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INTRODUCTION
Recent study of more than 20 000 children initiating dialysis therapy demonstrated that mortality rates in pediatric end-stage renal disease (ESRD) have improved dramatically between 1990 and 2010 [1 && ]. Despite this improvement, the overall mortality rates are still 30 times higher than in the general pediatric population, and cardiovascular disease remains the most common cause of death [1 && ]. The likely reason for such a high cardiovascular mortality is that children with chronic kidney disease (CKD) have extremely high prevalence of traditional and CKD-related cardiovascular risk factors [2] . Early markers of cardiomyopathy, such as left ventricular hypertrophy and dysfunction, and early markers of atherosclerosis, such as increased carotid artery intima-media thickness and carotid arterial wall stiffness, are frequently found in this patient population, especially in those on maintenance dialysis. Coronary artery calcification, known as an early marker of increased cardiovascular mortality in adults with CKD, can also be seen in children with advanced CKD. In the general population, elevated low density lipoprotein-cholesterol and systolic blood pressure levels during adolescence are independent predictors of adulthood coronary artery calcification [3] . In contrast, in children with CKD, disturbances in mineral metabolism are the likely cause of vascular calcification [4] .
In a recent review, Shroff et al. [5 && ] summarized a model of intact human vessels from CKD and dialysis patients to study the earliest changes involved in initiation of calcification in vivo. Experiments using this model showed that ectopic vascular calcification is a very similar process to physiological bone formation. Under conditions similar to CKD (increased calcium-phosphorus product), vascular smooth muscle cells (VSMCs) undergo phenotypic transformation and upregulate expression of mineralization-regulating proteins that are normally restricted to bone and cartilage. Dialysis vessels also showed VSMC loss due to apoptotic cell death, further increasing local concentration of calcium, thus promoting a vicious cycle of VSMC death, vesicle release, and accelerating calcification. The most interesting and current development in our understanding of the mechanisms of vascular calcification in CKD involves two relatively new factors: fibroblast growth factor 23 (FGF23) and Klotho. In the current review, we provide an update on the role of these factors in the pathogenesis of coronary artery calcification in patients with CKD.
KLOTHO, FIBROBLAST GROWTH FACTOR 23, AND VASCULAR CALCIFICATION
FGF23 and Klotho serve as major regulators of phosphorus homeostasis in both health and CKD. FGF23, a bone-derived hormone, is a potent phosphaturic hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25 (OH)2D, thus helping to mitigate hyperphosphatemia in CKD patients [6] . There are two forms of Klotho. One is a multifunctional single-pass transmembrane protein that belongs to the family 1 glycosidases (MW 130 kDa), and is expressed primarily in the renal tubules of the kidney and the choroid plexus in the brain, and another is free in circulation (soluble Klotho) [7] . Klotho exerts multiple actions on the kidney, including regulation of 1,25 Vitamin D3 production and modulation of urinary phosphate, calcium, and potassium excretion [7] . Klotho's gene product functions as a coreceptor for FGF23. Currently, it is well accepted from multiple animal models and human studies that elevated levels of FGF23 and decreased levels of Klotho are the earliest hormonal abnormalities involved in mineral metabolism in CKD [6, 7] . There is evidence emerging that disturbances in Klotho-FGF23 metabolism are an important contributor to vascular calcification in patients with CKD.
Lim
] for the first time described endogenous Klotho expression in human arteries and human aortic smooth muscle cells. Samples were collected from healthy people donating a kidney and CKD patients undergoing a renal transplant. Immunohistochemistry analysis demonstrated Klotho protein expression in the medial layer of arteries from healthy individuals, but marked reduction in arteries from patients with CKD. Importantly, reduced vascular Klotho expression in CKD patients was associated with extensive medial calcification. A subsequent series of mechanistic experiments in Klotho knockdown animals demonstrated that development of arterial calcification is through a Runx2 and myocardin-serum response factor-dependent pathway; vascular cells are Klotho-dependent target tissue for FGF23; and vitamin D receptor activators can restore procalcific stress and Klotho expression and unmask FGF-23 anticalcific effects. The authors concluded that local vascular Klotho is an endogenous inhibitor of vascular calcification and also serves as a cofactor required for vascular FGF23 signaling.
The results of this study were confirmed by Fang et al. [9] who examined FGF23 and Klotho expression in an animal model of early CKD before evident hyperphosphatemia. The authors used the atherosclerosis-bearing low-density lipoprotein-deficient mouse (ldlr -/-) fed with high fat, western-type diets (40% of calories from fat). The CKD was induced using unilateral renal injury and contralateral nephrectomy. Vascular calcification and decreased expression of Klotho in the aorta were evident in mild CKD. As in the study by Lim et al.
[8 && ], Runx2 was identified as a critical transcription factor in osteoblast transition in the aorta. The study also found elevated levels of another osteocytic biomarker protein, scerostin, implicated in bone turnover of CKD [10] .
In another study, Hu et al. [11] found increased vascular tissue calcium content in CKD animals and in Klotho-deficient (Kl -/-) animals. As expected, Klotho was undetectable in Kl -/mice (Klotho knockout mice). Importantly, Klotho was significantly decreased in kidney and barely detectable in the blood and urine of CKD mice, indicating that CKD is a state of 'pan deficiency' of Klotho. In another set of experiments, Klotho levels and their effects on vascular calcification were compared in
KEY POINTS
Cardiovascular disease is the most common cause of death in children with advanced CKD.
Coronary artery calcification is frequent in children on maintenance dialysis.
Abnormal mineral metabolism is the likely cause of coronary artery calcification in CKD.
Increased FGF23 and Klotho deficiency are early abnormalities involved in the development of cardiac calcification in CKD. wild (WT), Kl -/þ , and transgenic (Tg-Kl) mice before and after CKD induction. Baseline Klotho was lower in K -/þ mice compared with WT and highest in Tg-Kl mice. Despite induction of CKD, transgenic mice that overexpressed Klotho had preserved levels of Klotho, enhanced phosphaturia, better renal function, and much less calcification compared with wild-type mice with CKD. Conversely, Klotho-haploinsufficient mice with CKD had undetectable levels of Klotho, worse renal function, and severe vascular calcification. This study determined that Klotho ameliorated vascular calcification by enhancing phosphaturia, preserving glomerular filtration, and directly inhibiting phosphate uptake by VSMCs. The authors speculated that Klotho replacement therapy may be important in slowing progression of CKD as well as preventing and reversing vascular calcification and other CKD complications.
The role of FGF23 in inducing coronary artery calcification was questioned in the study by Scialla et al. [12] . Among 1501 patients enrolled in the Chronic Renal Insufficiency Cohort study, 983 participants (65%) had prevalent coronary artery calcification and 693 (46%) had thoracic aortic calcification, each defined as an Agatston score of more than 0. Overall, there was no significant association between FGF23 and the prevalence or severity of coronary calcium. However, FGF23 was associated with the severity of thoracic aortic calcification in patients with a nonzero Agaston score. Interestingly, experimental data demonstrated no expression of FGF23 in human or mouse VSMCs or in normal or calcified mouse aortas. In contrast, higher levels of serum phosphate were strongly associated with coronary artery calcification independently of FGF23, and elevated phosphate concentrations induced calcification in vitro. The authors suggested that, while phosphate induces calcification, FGF23 may promote the progression, but not the genesis, of calcification in large vessels such as aorta. Similarly, Lindberg et al. [13] showed no impact of FGF23 on vascular calcification and endothelial response in bovine VSMC and in a murine ex-vivo model of endothelial function. Finally, Jimbo et al. [14] showed that FGF23 enhances phosphateinduced vascular calcification by promoting osteoblastic differentiation involving the extracellularsignal-regulated kinases (ERK1/2) pathway.
PEDIATRIC STUDIES: FIBROBLAST GROWTH FACTOR 23, KLOTHO, AND CORONARY ARTERY CALCIFICATION IN CHRONIC KIDNEY DISEASE
As in adults, similar changes in FGF23 and Klotho are observed in children with CKD. A recent pediatric study of 110 children with various stages of CKD showed that changes in FGF23 and Klotho levels are the earliest mineral abnormalities: even in the presence of well-controlled serum phosphorus, high FGF23 and low soluble Klotho levels are already seen [15 && ]. In this study, there was a strong inverse correlation between plasma FGF23 and estimated glomerular filtration rate (GFR) in the total cohort including patients with predialysis CKD, dialysis patients, and patients with functioning graft; Klotho levels decreased with decreasing GFR in the CKD stages 1-5 and in dialysis patients. Decreased Klotho levels were also associated with increased FGF23 levels in the CKD and dialysis patients. Transplanted patients also showed an inverse correlation between FGF23 and GFR, but no association was found between Klotho and GFR.
There are very few studies evaluating coronary calcification in children with CKD [2] . Most current studies have been performed by Srivaths et al. [16] [17] [18] . In their initial study, coronary artery calcification was assessed by ultrafast computerized tomogram in 16 patients receiving maintenance hemodialysis for more than 2 months [16] . Five (31%) of 16 patients had coronary artery calcification. Patients with coronary artery calcification were older, had longer dialysis vintage, lower cholesterol, and higher phosphorus and calcium-phosphorus product levels. Authors concluded that renal osteodystrophy control (high phosphorus and calciumphosphorus product) and malnutrition (low cholesterol) may contribute to coronary artery calcification development. Using stored samples from these patients, FGF23 level was measured and compared in children with and without coronary artery calcification [17] . Serum FGF23 was elevated in all 16 children on maintenance hemodialysis and was positively associated with serum phosphorus level. Children with coronary artery calcification had significantly higher serum FGF23 levels than children without coronary artery calcification. In a follow-up study, the computerized tomogram was repeated 1 year after the initial evaluation [18] . Three patients with initial coronary artery calcification were progressed based on increased Agatston score; one patient developed new and none of the patients resolved coronary artery calcification. Not surprisingly, children with progressive coronary artery calcification had higher serum phosphorus and FGF23 levels. Interestingly, all but one patient with no calcification at baseline remained calcificationfree. This suggests the presence of protective factors such as higher use of noncalcium-based phosphate binders (sevelamer), genetic factors, and higher levels of calcification inhibitors. As most of the patients without coronary artery calcification remained calcification-free at follow-up, the authors did not recommend routine screening by computerized tomogram in all pediatric CKD patients, due to relatively high radiation exposure.
FIBROBLAST GROWTH FACTOR 23 AND KLOTHO CONTROL AS POTENTIAL THERAPEUTIC TARGET IN CHRONIC KIDNEY DISEASE PATIENTS
As a decrease in serum FGF23 is one of the earliest abnormalities of mineral metabolism observed in CKD, monitoring of this factor may be important in our understanding of the disease progression and potential therapeutic target in clinical practice, even in the early stages of CKD.
Lau et al. [19] tested two vitamin D receptor agonists in a mouse CKD model wherein dietary phosphate loading induced aortic medial calcification. Mice were given intraperitoneal calcitriol or paricalcitol physiological doses three times per week for 3 weeks. Treatment with these vitamin D receptor agonists was associated with half of the aortic calcification compared with no therapy. No difference between the two agents was found. Vitamin D receptor agonist therapy was associated with increased serum and urine Klotho levels, increased phosphaturia, correction of hyperphosphatemia, and lowering of serum FGF23. Interestingly, in the setting of a high phosphate diet, serum parathyroid hormone (PTH) and calcium levels were not significantly altered by treatment. The study concluded that Klotho was upregulated by vitamin D receptor agonist therapy independently of changes in serum parathyroid and calcium.
Block et al. [20] determined FGF23 and coronary artery calcification as secondary end-points in the randomized placebo-controlled pilot clinical trial of safety and efficacy of different phosphate-binders in patients with moderate CKD and normal or nearnormal serum phosphorus concentration. Treatment with phosphate binders significantly lowered serum and urinary phosphorus and attenuated progression of secondary hyperparathyroidism, but it resulted in the progression of coronary artery and abdominal aortic calcification, particularly in those randomized to the calcium acetate arm. The effects on intact FGF23 were different by binder type: patients treated with sevelamer carbonate, a noncalcium-based phosphate binder, experienced a significant decrease in intact FGF23 (P ¼ 0.002 versus placebo), whereas those patients treated with calcium acetate had a significant increase (P ¼ 0.03 versus placebo) and those patients treated with lanthanum carbonate were no different compared with placebo. The authors concluded that the safety and efficacy of phosphate binders in patients with CKD and normal serum phosphorus remain uncertain. To date, there have been no pediatric clinical trials in children with CKD assessing the effect of phosphate binders on FGF23 or Klotho levels.
Another study of adults on maintenance dialysis showed that values of FGF23 were lower in patients receiving short daily hemodialysis when compared with conventional hemodialysis (three times a week), despite greater use of vitamin D sterols and equivalent serum phosphorus and PTH concentrations [21] . The authors suggested that FGF23 levels may be a more sensitive biomarker of cumulative phosphate burden than single or multiple phosphorus determinations and a better marker to assess dialysis adequacy than currently utilized Kt/V.
CONCLUSION
Cardiac calcification is present and progresses in children with advanced CKD. Animal and human studies determined that CKD is a state of Klotho deficiency and elevated FGF23, the earliest markers of abnormal bone metabolism and factors associated with inducing (Klotho) or progression of (FGF23) coronary artery calcification. Future studies should determine whether correction of Klotho and FGF23 is associated with the regression of coronary artery calcification and improving of cardiovascular outcomes in patients with CKD.
